Ten years of antipsychotic prescribing to children: A Canadian population-based study

Canadian Journal of Psychiatry

Volumn 57, Issue 1, 2012, Pages 52-58

  Alessi Severini, Silvia ^a   Biscontri, Robert G ^b   Collins, David M ^a   Sareen, Jitender ^c   Enns, Murray W ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Adolescents; Antipsychotics; Children; Prescribing

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; LEVOMEPROMAZINE; METHYLPHENIDATE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CANADA; CHILD; CONDUCT DISORDER; DRUG INDICATION; DRUG USE; FEMALE; GENERAL PRACTITIONER; HEALTH CARE ACCESS; HUMAN; JUVENILE; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; REFERENCE DATABASE; SCHIZOPHRENIA; SCHOOL CHILD; TIC;

EID: 84863664132     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205700109     Document Type: Article

References (33)

1. Health Canada. Drug product database [Internet]. Ottawa (ON): Health Canada; [date of publication unknown] [cited 2011 Apr 29].
2. Official product monographs. Available from: http://www.hc-sc.gc.ca/dhp- mps/prodpharma/databasdon/index-eng.php.
3. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009;194:158-164.
4. DelBello MP, Chang K, Welge JA, et al. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord. 2009;11:483-493.
5. Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry. 1998;43:596-604. (Pubitemid 28518689)
6. Campbell M, Grega DM, Green WH, et al. Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol. 1983;6:207-222. (Pubitemid 14235232)
7. Scahill L, Koenig K, Carroll DH, et al. Risperidone approved for the treatment of serious behavioral problems in children. J Child Adolesc Psychiatr Nurs. 2007;20:188-190.
8. Stachnik JM, Nunn-Thompson C. Use of atypical antipsychotics in the treatment of autistic disorder. Ann Pharmacother. 2007;41:626-634. (Pubitemid 46625485)
9. Malone RP, Waheed A. The role of antipsychotics in the management of behavioural symptoms in children and adolescents with autism. Drugs. 2009;69:535-548.
10. Chen CY, Gerhard T, Winterstein AG. Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:187-195.
11. Thomson A, Maltezos S, Paliokosta E, et al. Risperidone for attention-deficit hyperactivity disorder in people with intellectual disabilities. Cochrane Database Syst Rev. 2009;15(2):CD007011.
12. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765-1773.
13. McIntyre RS, Jerrel JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med. 2008;162(10):929-935.
14. Calarge CA, Acion L, Kuperman S, et al. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009;19:101-109.
15. Panagiotopoulos C, Ronsley R, Davidson J. Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry. 2009;54:743-749.
16. Verma S, Liew A, Subramaniam M, et al. Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis. Aust N Z J Psychiatry. 2009;43:812-817.
17. Rani FA, Byrne PJ, Murray ML, et al. Paediatric atypical antipsychotic monitoring safety (PAMS) study: pilot study in children and adolescents in secondary- and tertiary-care settings. Drug Saf. 2009;32:325-333.
18. Jerrell JM, Bacon J, Burgis JT et al. Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents. J Adolesc Health. 2009;45:70-76.
19. Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol. 2009;19:415-422.
20. Doey T, Handelman K, Seabrook JA, et al. Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry. 2007;52:363-368. (Pubitemid 46997310)
21. Kozyrskyj AL, Mustard CA. Validation of an electronic, population-based prescription database. Ann Pharmacother. 1998;32:1152-1157. (Pubitemid 28543459)
22. Alessi-Severini S, Biscontri RG, Collins DM, et al. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006. Psychiatr Serv. 2008;59(5):547-553.
23. Kalverdijk LJ, Tobi H, van den Berg PB, et al. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv. 2008;59:554-560.
24. Rani F, Murray ML, Byrne PJ, et al. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008;121:1002-1009.
25. Schubert I, Lehmkuhl G. Increased antipsychotic prescribing to youths in Germany. Psychiatr Serv. 2009;60:269.
26. Hsia Y, Maclennan K. Rise in psychotropic drug prescribing in children and adolescents during 1992-2001: a population-based study in the UK. Eur J Epidemiol. 2009;24:211-216.
27. Mitchell B, Carlton B, Smith A, et al. Trends in psychostimulant and antidepressant use by children in 2 Canadian provinces. Can J Psychiatry. 2008;53(3):152-159. (Pubitemid 351469374)
28. Kronenberger WG, Giauque AL, Lafata DE, et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334-347. (Pubitemid 47067957)
29. Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008;69(Suppl 4):9-14.
30. Zeni CP, Tramontina S, Ketzer CR, et al. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol. 2009;19(5):553-561.
31. Harris G, Carey B. Researchers fail to reveal full drug pay. The New York Times (online edition). 2008 Jun 8; US Section. Available from: http://www.nytimes.com/2008/06/08/us/08conflict.html.
32. Shankar BR. Quetiapine-induced leucopenia and thrombocytopenia. Psychosomatics. 2007;48:530-531. (Pubitemid 350074407)
33. Health Canada. Canadian Adverse Reaction Newsletter. Ottawa (ON): MedEffect™ Canada; 2009;19(2).